NORTHRIDGE, Calif. & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Avita Medical Ltd. (ASX: AVH), the regenerative medicine company, today announced that the United States Food and Drug Administration (FDA) has approved the Company’s investigational device exemption (IDE) feasibility study for the use of ReCell® Spray-On-Skin™ in the treatment of hypertrophic dyspigmented scars: i.e., raised and/or discoloured scars.
